Loading...
•
Mar 31, 2021
Capricor Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Capricor Therapeutics reported a net loss of $5.2 million, or $0.23 per share, for the first quarter of 2021. As of March 31, 2021, the Company’s cash and cash equivalents totaled approximately $41.9 million.
Progress made across clinical and preclinical programs.
Executed an exclusive, worldwide licensing agreement with Johns Hopkins University to expand engineered exosome platform technology.
Ongoing discussions with potential collaborators and the FDA to evaluate paths towards commercialization of the DMD program.
Continued progress in enrollment of INSPIRE clinical trial treating severe COVID-19 patients, with top-line data expected in the third quarter.
Forward Guidance
Capricor believes that based on the current operating plan and financial resources, the Company expects that the cash, cash equivalents and marketable securities will be sufficient to cover expenses and capital requirements through at least the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...